{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:03:00Z","timestamp":1793289780772,"version":"4.5.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Globally, liver cancers are the second most lethal malignancy after lung cancer (0.83 million deaths in 2020). Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer and is typically associated with liver fibrosis or cirrhosis. HCC diagnosis relies on histologic examination of surgical specimens or conventional tissue biopsy material. However, standard tissue biopsies are invasive and often do not accurately reflect the tumor heterogeneity. On the other hand, the use of liquid biopsies, represented mainly by circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), has greatly increased in the past 2 decades. Indeed, liquid biopsies are a noninvasive, repeatable, and sensitive approach to studying tumor biology.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Content<\/jats:title>\n                  <jats:p>This review describes current clinical applications of ctDNA analysis in the management of patients with chronic liver disease, cirrhosis, and HCC. There is a substantial clinical potential of ctDNA, but interventional studies are still lacking for the moment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Detection of ctDNA in both asymptomatic individuals and high-risk patients (with chronic liver disease or cirrhosis) contributes to the early diagnosis of HCC. ctDNA analysis also offer tremendous information on the tumor burden and on the risk of early recurrence. The implementation of ctDNA analysis, in association with classical tumor markers (e.g., alpha-fetoprotein), may improve (a) HCC screening in high-risk patients, (b) stratification of the recurrence risk after surgery, and (c) prognosis evaluation of patients with HCC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvad168","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:37:47Z","timestamp":1699965467000},"page":"33-48","source":"Crossref","is-referenced-by-count":16,"title":["Circulating Tumor DNA Clinical Applications in Hepatocellular Carcinoma: Current Trends and Future Perspectives"],"prefix":"10.1093","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-154X","authenticated-orcid":false,"given":"Thomas","family":"Bardol","sequence":"first","affiliation":[{"name":"Laboratory of Rare Human Circulating Cells, University Hospital Center, University of Montpellier , Montpellier , France"},{"name":"CREEC, MIVEGEC, University of Montpellier, CNRS, IRD , Montpellier , France"},{"name":"Department of Digestive Surgery and Transplantation, Digestive and Mini-invasive Surgery Unit, Montpellier University Hospital, Montpellier University , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges-Philippe","family":"Pageaux","sequence":"additional","affiliation":[{"name":"Hepatology and Liver Transplant Unit, Saint Eloi University Hospital, Montpellier University , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saint Eloi University Hospital Center, Montpellier University , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6401-2903","authenticated-orcid":false,"given":"Catherine","family":"Alix-Panabi\u00e8res","sequence":"additional","affiliation":[{"name":"Laboratory of Rare Human Circulating Cells, University Hospital Center, University of Montpellier , Montpellier , France"},{"name":"CREEC, MIVEGEC, University of Montpellier, CNRS, IRD , Montpellier , France"},{"name":"European Liquid Biopsy Society (ELBS), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"2024012006453546200_hvad168-B1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"2024012006453546200_hvad168-B2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024012006453546200_hvad168-B3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41575-022-00620-y","article-title":"Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024012006453546200_hvad168-B4","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov"},{"key":"2024012006453546200_hvad168-B5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/SLA.0b013e31821ad884","article-title":"Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria","volume":"254","author":"Lim","year":"2011","journal-title":"Ann Surg"},{"key":"2024012006453546200_hvad168-B6","first-page":"241","article-title":"[Nuclear acids in human blood plasma]","volume":"142","author":"Mandel","year":"1948","journal-title":"C R Seances Soc Biol Fil"},{"key":"2024012006453546200_hvad168-B7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"2024012006453546200_hvad168-B8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"key":"2024012006453546200_hvad168-B9","doi-asserted-by":"crossref","first-page":"eaax7533","DOI":"10.1126\/scitranslmed.aax7533","article-title":"Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer","volume":"12","author":"Luo","year":"2020","journal-title":"Sci Transl Med"},{"key":"2024012006453546200_hvad168-B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-017-0500-7","article-title":"The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med"},{"key":"2024012006453546200_hvad168-B11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"2024012006453546200_hvad168-B12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00432-005-0049-5","article-title":"The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma","volume":"132","author":"Ren","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024012006453546200_hvad168-B13","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.bjc.6604034","article-title":"Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma","volume":"97","author":"Tokuhisa","year":"2007","journal-title":"Br J Cancer"},{"key":"2024012006453546200_hvad168-B14","doi-asserted-by":"crossref","first-page":"E238","DOI":"10.25011\/cim.v34i4.15366","article-title":"Quantification of plasma hTERT DNA in hepatocellular carcinoma patients by quantitative fluorescent polymerase chain reaction","volume":"34","author":"Yang","year":"2011","journal-title":"Clin Invest Med"},{"key":"2024012006453546200_hvad168-B15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12253-011-9438-z","article-title":"Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma","volume":"18","author":"Huang","year":"2012","journal-title":"Pathol Oncol Res"},{"key":"2024012006453546200_hvad168-B16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/PAT.0b013e328353a24c","article-title":"Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma","volume":"44","author":"Chen","year":"2012","journal-title":"Pathology"},{"key":"2024012006453546200_hvad168-B17","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/s12072-013-9481-9","article-title":"Circulating free DNA in the progression of liver damage to hepatocellular carcinoma","volume":"7","author":"Piciocchi","year":"2013","journal-title":"Hepatol Int"},{"key":"2024012006453546200_hvad168-B18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cca.2006.12.029","article-title":"Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma","volume":"379","author":"Tangkijvanich","year":"2007","journal-title":"Clin Chim Acta"},{"key":"2024012006453546200_hvad168-B19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1373\/clinchem.2008.104653","article-title":"Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma","volume":"54","author":"Chan","year":"2008","journal-title":"Clin Chem"},{"key":"2024012006453546200_hvad168-B20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7150\/ijms.6745","article-title":"Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B virus associated hepatocellular carcinoma","volume":"11","author":"Han","year":"2014","journal-title":"Int J Med Sci"},{"key":"2024012006453546200_hvad168-B21","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.3748\/wjg.v20.i16.4723","article-title":"MT1M And MT1G promoter methylation as biomarkers for hepatocellular carcinoma","volume":"20","author":"Ji","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2024012006453546200_hvad168-B22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1515\/cclm-2013-0885","article-title":"Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma","volume":"52","author":"Huang","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2024012006453546200_hvad168-B23","doi-asserted-by":"crossref","first-page":"e0174265","DOI":"10.1371\/journal.pone.0174265","article-title":"Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma","volume":"12","author":"Holmila","year":"2017","journal-title":"PLoS One"},{"key":"2024012006453546200_hvad168-B24","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/nmat4997","article-title":"Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma","volume":"16","author":"Xu","year":"2017","journal-title":"Nat Mater"},{"key":"2024012006453546200_hvad168-B25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ebiom.2018.03.029","article-title":"Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma","volume":"30","author":"Oussalah","year":"2018","journal-title":"EBioMedicine"},{"key":"2024012006453546200_hvad168-B26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/10715762.2018.1443448","article-title":"Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy","volume":"52","author":"Li","year":"2018","journal-title":"Free Radic Res"},{"key":"2024012006453546200_hvad168-B27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/hep.30244","article-title":"Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation","volume":"69","author":"Kisiel","year":"2019","journal-title":"Hepatology"},{"key":"2024012006453546200_hvad168-B28","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1136\/gutjnl-2019-318882","article-title":"Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma","volume":"68","author":"Cai","year":"2019","journal-title":"Gut"},{"key":"2024012006453546200_hvad168-B29","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41467-020-17316-z","article-title":"Non-invasive early detection of cancer four years before conventional diagnosis using a blood test","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"2024012006453546200_hvad168-B30","doi-asserted-by":"crossref","first-page":"E1317","DOI":"10.1073\/pnas.1500076112","article-title":"Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients","volume":"112","author":"Jiang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024012006453546200_hvad168-B31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/hep4.1187","article-title":"Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: prevalence and risk factors","volume":"2","author":"Jiao","year":"2018","journal-title":"Hepatol Commun"},{"key":"2024012006453546200_hvad168-B32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1158\/1940-6207.CAPR-17-0235","article-title":"Prevalence of aflatoxin-associated TP53R249S mutation in hepatocellular carcinoma in Hispanics in South Texas","volume":"11","author":"Jiao","year":"2018","journal-title":"Cancer Prev Res"},{"key":"2024012006453546200_hvad168-B33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10238-018-0502-9","article-title":"Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma","volume":"18","author":"Marchio","year":"2018","journal-title":"Clin Exp Med"},{"key":"2024012006453546200_hvad168-B34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"2024012006453546200_hvad168-B35","doi-asserted-by":"crossref","first-page":"17862","DOI":"10.1038\/s41598-020-74494-y","article-title":"MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"2024012006453546200_hvad168-B36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21037\/atm.2019.12.154","article-title":"Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma","volume":"8","author":"Wang","year":"2020","journal-title":"Ann Transl Med"},{"key":"2024012006453546200_hvad168-B37","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/00365521.2020.1837928","article-title":"TERT Promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma","volume":"55","author":"Oversoe","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"2024012006453546200_hvad168-B38","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.1002\/ctm2.793","article-title":"Integrated analysis of circulating tumour cells and circulating tumour DNA to detect minimal residual disease in hepatocellular carcinoma","volume":"12","author":"Zhao","year":"2022","journal-title":"Clin Transl Med"},{"key":"2024012006453546200_hvad168-B39","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/cr.2015.126","article-title":"Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients","volume":"25","author":"Wen","year":"2015","journal-title":"Cell Res"},{"key":"2024012006453546200_hvad168-B40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jcmgh.2015.06.009","article-title":"Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy","volume":"1","author":"Ono","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2024012006453546200_hvad168-B41","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.27732","article-title":"DNA Methylation-based prognosis and epidrivers in hepatocellular carcinoma","volume":"61","author":"Villanueva","year":"2015","journal-title":"Hepatology"},{"key":"2024012006453546200_hvad168-B42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5483-x","article-title":"Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib","volume":"19","author":"Oh","year":"2019","journal-title":"BMC Cancer"},{"key":"2024012006453546200_hvad168-B43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41388-020-01519-1","article-title":"Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma","volume":"40","author":"von Felden","year":"2021","journal-title":"Oncogene"},{"key":"2024012006453546200_hvad168-B44","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1097\/MD.0000000000000722","article-title":"Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis","volume":"94","author":"Liao","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2024012006453546200_hvad168-B45","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cam4.2799","article-title":"Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med"},{"key":"2024012006453546200_hvad168-B46","doi-asserted-by":"crossref","first-page":"103112","DOI":"10.1016\/j.critrevonc.2020.103112","article-title":"International liquid biopsy standardization alliance white paper","volume":"156","author":"Connors","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024012006453546200_hvad168-B47","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1038\/d41586-020-00844-5","article-title":"The future of liquid biopsy","volume":"579","author":"Alix-Panabi\u00e8res","year":"2020","journal-title":"Nature"},{"key":"2024012006453546200_hvad168-B48","doi-asserted-by":"crossref","first-page":"E5503","DOI":"10.1073\/pnas.1508736112","article-title":"Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments","volume":"112","author":"Sun","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024012006453546200_hvad168-B49","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1038\/s41598-019-43572-1","article-title":"Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"2024012006453546200_hvad168-B50","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1002\/cam4.3230","article-title":"Exosomal microRNA-4661-5p-based serum panel as a potential diagnostic biomarker for early-stage hepatocellular carcinoma","volume":"9","author":"Cho","year":"2020","journal-title":"Cancer Med"},{"key":"2024012006453546200_hvad168-B51","doi-asserted-by":"crossref","first-page":"e22242","DOI":"10.1097\/MD.0000000000022242","article-title":"Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): a systematic review and meta-analysis","volume":"99","author":"Cui","year":"2020","journal-title":"Medicine (Baltimore)"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/70\/1\/33\/56253548\/hvad168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/70\/1\/33\/56253548\/hvad168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T06:48:07Z","timestamp":1705733287000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/70\/1\/33\/7420052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,14]]},"published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvad168","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,11,14]]}}}